Porton Pharma Solutions and OD Kingsley Life Sciences Form Partnership for Bio Conjugated Drug Development
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions (SHE: 300363) has announced a...
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions (SHE: 300363) has announced a...
The acquisition of contract development and manufacturing organization (CDMO) Catalent (NYSE: CTLT) by Novo Holdings...
Medtide Inc., a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides and based...
US-based contract development and manufacturing organization (CDMO) Cambrex has reached an agreement with Eli Lilly...
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...
China’s Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced plans...
Shanghai Duoning Biotechnology Co., Ltd, a prominent biopharmaceutical company in China, has entered into a...
WuXi AppTec Co., Ltd (SHA: 603259), the China-based Contract Development and Manufacturing Organization (CDMO) facing...
The People’s Government of Tianjin Municipality has unveiled two significant implementation plans to bolster the...
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359, OTCMKTS: WUXAY), a leading China-based Contract Development...
Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing...
Tigermed (SHE: 300347, HKG: 3347) has announced its intention to acquire a 40.5650% stake in...
Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on...
South Korea’s biosimilars giant, Celltrion Inc., is gearing up to expand into the contract development...
Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with...
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a...
SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry...
HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced...
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China,...
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...